title: Teicoplanin pharmacokinetics in pediatric patients.
abstract: BACKGROUND
  The incidence of methicillin-resistant Gram-positive bacteria infections in febrile neutropenic children is high. Teicoplanin is an alternative treatment to vancomycin in these patients but few pharmacokinetic studies of teicoplanin in children have been conducted and optimal dosages have not been well-established.
  
  
  OBJECTIVE
  To assess the pharmacokinetics of teicoplanin in combination with another antibiotic in Gram-positive infections in pediatric patients undergoing bone marrow transplantation and to determine the most appropriate dosage regimen for this type of patient.
  
  
  METHODS
  We studied 21 patients divided into 2 groups. In Group A (n = 9) the dosage regimen consisted of 3 loading doses of 10 mg/kg at 12-h intervals, followed by a maintenance dosage of 10 mg/kg/day. Group B (n = 12) received the same loading dose and a maintenance dosage of 20 mg/kg/day. Plasma teicoplanin concentrations were monitored in all patients from the second day after the start of treatment and periodically thereafter. Serum concentrations above 10 mg/l were established as desirable trough values.
  
  
  RESULTS
  In Group A trough values > 10 mg/l were not reached in five patients and treatment was modified owing to persistent fever. In Group B all patients attained trough values > 10 mg/l. Tolerance to treatment was excellent.
  
  
  CONCLUSIONS
  In febrile neutropenic pediatric patients undergoing bone marrow transplantation, maintenance dosages of teicoplanin between 15 and 20 mg/kg/day assure serum concentrations above 10 mg/l. Dosages of 10 mg/kg/day do not assure serum through values above 10 mg/l.
authors.affiliation: Hospital Materno-Infantil Vall d'Hebron, Universidad Autónoma de Barcelona, Spain.
authors.forename: G
authors.initials: G
authors.lastname: Dufort
authors.forename: C
authors.initials: C
authors.lastname: Ventura
authors.forename: T
authors.initials: T
authors.lastname: Olivé
authors.forename: J J
authors.initials: JJ
authors.lastname: Ortega
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D001398:Aztreonam / Q000494:pharmacology; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002442:Ceftazidime / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D006094:Gram-Positive Bacteria / Q000187:drug effects; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008826:Microbial Sensitivity Tests; D008997:Monobactams / Q000494:pharmacology; D017334:Teicoplanin / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D008997:Monobactams; D017334:Teicoplanin; D002442:Ceftazidime; D001398:Aztreonam